epidermolysis bullosa

[Abeona Therapeutics Inc.] Abeona Therapeutics, Inc. announced that target enrollment has been achieved in its pivotal Phase III VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

[Laboratory Investigation] Scientists showed that collagen XVII, a niche for epidermal stem cells, helped stabilize epidermal patterns.

[Journal of Investigative Dermatology] Investigators demonstrated that Kelch-like protein 24 (KLHL24) played a role in hair maintenance by regulating the cytoskeleton structure of hair follicle stem cells (HFSCs) and highlighted the importance of the ubiquitin-proteasome system in the stability of HFSCs.

[AVITA Medical, Inc.] AVITA Medical, Inc. announced that preclinical data successfully established proof of concept in two key areas of cell-based gene therapy – skin rejuvenation and epidermolysis bullosa.

[British Journal of Dermatology] Investigators explain the principles of different approaches of gene therapy, summarize its journey and discuss its current and future impact in recessive dystrophic epidermolysis bullosa.

[Krystal Biotech, Inc.] Krystal Biotech, Inc. announced that the last participant has completed the GEM-3 study, Krystal’s pivotal Phase III clinical trial evaluating investigational beremagene geperpavec (B-VEC) as a topical gene therapy for the treatment of dystrophic epidermolysis bullosa.